HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection (HEARTBiT)
HEARTBiT: A Novel Multi-Marker Blood Test for Management of Acute Cardiac Allograft Rejection
Sponsor: Canadian Institutes of Health Research (CIHR)
This observational or N/A phase trial investigates Heart Diseases and Heart Failure and is currently ongoing. Canadian Institutes of Health Research (CIHR) leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
13 versions recorded-
May 2025 — Present [monthly]
Active Not Recruiting
-
Jan 2025 — May 2025 [monthly]
Active Not Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 8 earlier versions
-
Jun 2022 — Jun 2023 [monthly]
Recruiting
-
Dec 2021 — Jun 2022 [monthly]
Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Nov 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jul 2019 — Nov 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Jul 2019 [monthly]
Not Yet Recruiting
-
Aug 2018 — Jan 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Canadian Institutes of Health Research (CIHR)
- Duke University
- PROOF Centre of Excellence
- St. Paul's Hospital, Canada
- Toronto General Hospital
- University of British Columbia
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .